Intarcia Reveals New Insights at EASD Meeting Characterizing the Burden of Poor Control and Non-Adherence to Anti-Diabetic Therapies – Data indicate 58% non-adherence to second-line treatments in T2D patients, significantly higher than patients report and...
Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration LEXINGTON, Mass.–(Sep 17, 2014)– Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has initiated a Phase 1 clinical trial of...
Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results – FREEDOM-1 study showed that ITCA 650 demonstrated positive results when added to standard oral diabetes medications. All...
Chimerix Announces Emergency Investigational New Drug Applications for Brincidofovir Authorized by FDA for Patients With Ebola Virus Disease DURHAM, N.C., Oct. 6, 2014 (GLOBE NEWSWIRE) — Chimerix, Inc. (Nasdaq:CMRX), a biopharmaceutical company developing novel,...
Actavis to Acquire Durata Therapeutics, Inc. – Lead Product DALVANCE™ a Novel Antibiotic for Unmet Medical Need in Hospital and Outpatient Settings – Enhances Actavis’ Long-term Growth Profile 2015+ – Experienced Development and Commercial Team...
Recent Comments